Iovance Biotherapeutics has filed for a mixed shelf offering with the SEC. The size of the offering has not been disclosed, which may create uncertainty among investors. This could lead to short-term volatility in the stock price, but the overall impact is uncertain due to the lack of information on the size of the offering.